Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib
Topline results from the full FIREFLY-1 trial population expected in Q1 2023
Day One plans to initiate a pivotal Phase 3 clinical trial of tovorafenib in front-line pediatric low-grade glioma (pLGG), with first patient dosed expected in Q3 2022
Company to host conference call and webcast June 13, at 8:00 a.m. Eastern Time
Conference Call and Webcast Information
Day One will host a conference call and webcast, June 13, 2022, at 8:00 a.m. Eastern Time. To participate by telephone, please dial 844-713-6132 (Domestic) or 1-213-320-2543 (International). The conference ID number is 3568447. The webcast will be made available for replay on the Company's website beginning approximately two hours after the event and will be available for 30 days following the live presentation.
https://finance.yahoo.com/news/day-one-announces-positive-initial-210000609.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.